Introduction
In hospital practice, improving antimicrobial prescriptions on a dayto-day basis is a complex undertaking. It involves processing of an enormous amount of clinical data, as shown by a recent prevalence study in US acute care hospitals revealing that almost half of the patients had received at least one antimicrobial drug at some point during their hospital stay. 1 Additionally, since the status of several clinical variables is subject to change over time, prescriptions have to be validated repetitively. According to the Society for Healthcare Epidemiology of America (SHEA) and the IDSA guidelines, 2 the pharmacist who performs the prospective audit and feedback should have received appropriate training in antimicrobial stewardship. However, several centres do not have access to specialized personnel, making the task more challenging. [3] [4] [5] Nevertheless, the demonstrated benefits of optimizing antimicrobial prescriptions and of decreasing their overall consumption have prompted most acute care centres to implement antimicrobial stewardship programmes (ASPs). 3, [6] [7] [8] In the near future, more centres will include ASPs in their practice, as several scientific or professional organizations [9] [10] [11] [12] [13] are actively promoting this approach. 9, 10, 14 A core strategy of antimicrobial stewardship is prospective audit and feedback (PAF), defined by the IDSA as an intervention that engages the provider after an antibiotic is prescribed. 2 This process is labour and time intensive when performed manually. 15 Hospitals are increasingly relying on computerized clinical decision-support systems to supply their ASP with the relevant data and identify patients who should be prioritized for review. [15] [16] [17] [18] [19] V C The Author 2016. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For Permissions, please email: journals.permissions@oup.com.
For this study, the Antimicrobial Prescription Surveillance System (APSS), a computerized clinical decision-support system designed to assist an ASP team, was used. APSS monitors the clinical information of a patient; as new information becomes available, it verifies that the ongoing treatment remains appropriate according to contraindications related to inappropriate drug-drug interactions, drug-bug or drug-laboratory mismatches, cheaper alternatives, maximum daily dose, maximum and minimum dose and frequency, maximum duration and route of administration. The evaluation takes into account conditions such as cystic fibrosis, haemodialysis, morbid obesity and previous Pseudomonas aeruginosa infections.
The aim of this study was to evaluate the longitudinal impact of an ASP with PAF using APSS on hospital length of stay (LOS), antimicrobial use and costs, and non-concordance with the guidelines for prescribing antimicrobials.
Methods

Setting and study design
We conducted a retrospective cohort study of all hospitalized adult patients (!18 years) who received intravenous or oral antimicrobials at the Centre Hospitalier Universitaire de Sherbrooke (CHUS) between 18 August 2008 and 18 August 2013. The CHUS is a 677 bed hospital with two geographically distinct centres that provide secondary and tertiary care to the inhabitants of the administrative region of Estrie in the province of Quebec, Canada. Patients from the psychiatric and maternity units were excluded because of their sporadic usage of systemic antimicrobials.
Intervention
The APSS-initiated PAF strategy was implemented on 18 August 2010. For the first year, a 0.5 full-time equivalent clinical pharmacist was assigned to APSS on weekdays (Monday to Friday). Thereafter, it was increased to one full-time pharmacist. The first pharmacist who worked with APSS was specialized in infectious diseases, and was in charge of training all four pharmacists on their first week in the ASP. An infectious diseases physician assisted the pharmacists 5 h per week to review their potential interventions prior to contacting prescribers. From August 2008 to July 2010, no other systematic stewardship activities were conducted at the CHUS.
APSS receives hourly clinical data from the CHUS electronic health record system, QuadraMed's Computerized Patient Record, using a Health Level 7 data communication interface. These data include information on demographics, admission, vital signs and pharmacy, laboratory, radiology and microbiology variables. The CHUS does not possess a computerized physician-order entry system, and written prescriptions are still used. Prescriptions are entered in the electronic health record system later by technical assistants at the pharmacy department, creating a 1-2 h lag for the pharmacy interface. APSS is an asynchronous system that facilitates the post-prescription review process by reorganizing relevant clinical information and producing alerts supported by references for potentially inappropriate prescriptions using validated algorithms derived from published guidelines and expert opinions. Severity scores enable antimicrobial stewardship pharmacists to prioritize patients who require most attention. APSS's knowledge base includes evaluation rules for inappropriate drug-drug interactions, redundant spectrums, drug-bug mismatches, cheaper alternatives, dose adjustments, duration of treatment and switch from intravenous to oral therapy.
Outcomes
The outcomes of interest were average LOS for patients with antimicrobials, antimicrobial consumption in DDDs per 1000 inpatient days (DDDs/1000 PDs), days of therapy (in calendar days) per 1000 inpatient days (DOT/1000 PDs), antimicrobial spending using fixed prices (a single price for each antimicrobial taken at the start of the intervention) and variable prices (monthly average price by 4 week periods for each antimicrobial), and the percentage of non-concordance with the guidelines for prescribing antimicrobials (inappropriate DOT identified by APSS/total DOT). All costs are reported in Canadian dollars. One DOT represents the administration of any antimicrobial agent on a given day and DDDs were defined as per the WHO standards. The anonymized outcome data were extracted from the CHUS clinical data warehouse, 20 and the antimicrobial spending was calculated from the pharmacy financial database, which includes spending when the antimicrobials are taken out of the hospital store, not when they are consumed.
Statistical analysis
The methodology described by Wagner et al. 21 was used to evaluate the longitudinal impact of the APSS-initiated PAF strategy on the outcomes of interest. The segmented regression analysis of interrupted time series allowed assessment of the changes in the level and trend of our outcomes of interest between pre-intervention data (August 2008 to July 2010) and the intervention phase (August 2010 to July 2013). We combined the data into 4 week periods (of which there were 65; 26 periods before and 39 periods during the intervention). The time series were modelled using a stepwise approach. To evaluate the stationarity of outcomes, an augmented Dickey-Fuller test was performed at a 5% level. At each modelling step, we graphically plotted the predictions against the observations and plotted the residuals against a normal distribution. We used the Durbin-Watson statistics to detect autocorrelation in residuals and considered a value close to 2 to indicate non-autocorrelation. 22, 23 To validate whether the residuals were randomly distributed, we tested their normality using the JarqueBera test, which confirmed their homoscedasticity. 24 To identify the most parsimonious model, we used bilateral significance tests for the model parameters. We used a P value of <0.05 as a threshold for all statistical tests. We analysed the data using the PROC AUTOREG statement in SAS version 9.2 (SAS Institute, Cary, NC) with a lag order of 13 to take into account the annual seasonality.
Because the introduction of generic antimicrobials is associated with decreased costs and often with an increased use of antimicrobials, we analysed the impact of the introduction of generic imipenem in October 2010 and of generic meropenem in September 2012 by creating two cointerventions. We maintained the significant co-interventions in the final model. To evaluate the evolution of non-concordance with the antimicrobial prescription guidelines, we used APSS to evaluate pre-intervention data with the same set of surveillance rules as for the ASP period.
For an easier interpretation of the results, we compared the final value as predicted by the linear trend post-intervention of the ASP period of each outcome with its conservative mean and maximum prediction value. 25 The conservative mean is calculated as the average value of the outcome for the last six periods before the intervention. The maximum prediction value is the linear projection at period 65 of the pre-intervention trend.
Results
Overall, we included 40 605 hospitalization episodes for 35 778 patients who received antimicrobials. Gender and age distributions did not change throughout the study period. During the intervention, the pharmacists made 5665 recommendations to prescribers, of which 91% (n ¼ 5156) were accepted. The most frequent interventions were dosing adjustment (n ¼ 1317, 26%), switch from intravenous to oral therapy (n ¼ 832, 16%), immediate discontinuation of treatment (n ¼ 641, 13%), scheduling end of treatment (n ¼ 486, 9%), adjustment based on antimicrobial Nault et al.
serum levels (n ¼ 451, 8%), adjustment according to microbiology results (n ¼ 354, 7%) and switching to cheaper but equally effective alternatives (n ¼ 121, 3%). The antimicrobials most frequently targeted by recommendations were piperacillin/tazobactam (n ¼ 1133, 20%), vancomycin (n ¼ 1020, 18%), ciprofloxacin (n ¼ 963, 17%) and meropenem (n ¼ 283, 5%).
Average length of stay
We compared the average LOS trends between the patients who received antimicrobials and those who did not. The patients who did not receive antimicrobials showed a slow but continuous increase in average LOS, without a significant change in the level or trend after the intervention. However, although we observed a similar increasing trend in the average LOS before the intervention (0.4 days, P < 0.01) for the patients who received antimicrobials, we observed a reverse trend in the ASP period, with a steady decrease throughout the following 3 years. As shown in Figure 1 , there was a significant level change (À0.92 days, P < 0.01; intercept 11.4 days) in the average LOS immediately after the beginning of the intervention as well as a significant negative trend (À0.08 days, P < 0.01) ( Table 1) . We observed an 18.6% reduction in average LOS between the predicted value by linear trend in period 65 and the conservative mean and a 27.4% reduction compared with the maximum predicted value (Table 2 ).
Antimicrobial consumption
We observed similar antimicrobial consumption trends in Figure 2 for DOT/1000 PDs and DDD/1000 PD in the pre-intervention and ASP periods. The APSS-initiated PAF strategy had an immediate impact, indicated by a change in level, as well as a sustained longterm effect, indicated by a change in slope, on antimicrobial consumption. From a base level of 301 DOT/1000 PDs with a significant upward trend (12 DOT/1000 PDs, P < 0.01), the intervention had significant changes in level (À28, P ¼ 0.01; intercept 301 DOT/1000 PDs) and trend (À1.43 DOT/1000 PDs, P < 0.03). The DDDs/1000 PDs followed a similar pattern (Table 1) . Comparing the final value as predicted by linear trend at period 65 of DOT/1000 PDs with the conservative mean and the maximum prediction value, we observed a reduction of antimicrobial consumption of 11% and 21.8%, respectively. We also observed a reduction in DDDs/1000 PDs of 12.2% when compared with the conservative mean and 23.8% compared with the maximum prediction value. Figure 3 illustrates the antimicrobial spending measured using variable prices. Starting with a significant upward shift ($8816, P < 0.01), it shows important changes in both level and trend after the intervention. Antimicrobial spending with variable prices had a significant change in level (À$13 589, P < 0.03; intercept $86 557) and a sustained downward trend (À$1477, P ¼ 0.01) after the intervention. Antimicrobial spending using fixed prices displayed similar changes, including a confounding variable with a co-intervention for the introduction of generic meropenem in period 53. The confounding co-intervention had significant changes in level ($39 669, P ¼ 0.05) and trend (À$3756, P < 0.01). In addition, the intervention had a significant impact on antimicrobial spending using fixed prices, with significant changes in level (À$19 649, P < 0.01; intercept $74 683) as well as trend (À$1881, P ¼ 0.05) ( Table 1) . Comparing the final value as predicted by the linear trend of antimicrobial spending with variable prices with the conservative mean and the maximum prediction value, we observed reductions of 33.6% and 49.0%, respectively. Comparing the final value as predicted by the 
Antimicrobial spending
Non-concordance with antimicrobial prescribing guidelines
There was a significant immediate change in the proportion (À2.3%, P ¼ 0.04; intercept 41%) of non-concordance with local guidelines for prescribing antimicrobials. Like the initial upward trend, the decreasing trend observed in the intervention period ( Figure 4 ) was not significant (Table 1) . Comparing the nonconcordance final value as predicted by the linear trend after 3 years with the conservative mean and the maximum prediction values, we observed reductions of 4.0% and 5.5%, respectively.
Discussion
The implementation of an ASP with a PAF strategy based on APSS had a positive impact on several outcomes: it reduced antimicrobial consumption and spending, non-concordance with antimicrobial prescribing guidelines, and the average LOS for patients who received antimicrobials. The magnitude of the decrease in the first three outcomes and their persistence over 3 years is important even when we consider the positive impacts following the implementation of a PAF strategy as reported in the literature (which mostly do not involve computerized clinical decision support systems). 26 To our knowledge, this is the first study to demonstrate a sustained reduction in the average LOS for hospitalized adults following a PAF initiative.
Evidence to prove that PAF strategies provide a clear benefit for patient outcomes is scarce 9,10,26,27 and of relatively low quality. A systematic review of 18 studies evaluating the effectiveness of PAF strategies on patient outcomes reported only four significant differences with respect to one or more patient outcomes (mortality, readmission, LOS and Clostridium difficile infection). The only study that found a significant difference in LOS was performed >10 years ago and it involved a small number of patients during a 3 month period of evaluation; their computerized clinical decisionsupport system only included alerts based on microbiological results. 28 As we introduced a level of surveillance that had never been seen in our centre, most physicians eventually knew that their prescriptions were being monitored and evaluated, and this awareness could have led to behaviour changes, an indirect but welcome consequence of our intervention. Several authors have highlighted this Hawthorne effect in stewardship and infection Measures the long-term impact over time of the intervention. c For patients who received antimicrobials. d There were significant level ($39 669, P 0.01) and trend (À$3756, P < 0.01) changes after the introduction of generic meropenem at period 53. Nault et al.
control interventions. 7, 29 The positive impact of the intervention on various outcomes went further than what could be anticipated based on the proportion of patients for whom a recommendation had been made. We think that repeated recommendations to physicians might have induced a learning process, making them rethink the way they were using antimicrobials in a way that might have increased the impact of the ASP.
In this study, we reported a significant hospital-wide reduction in the average LOS of patients who received antimicrobials. This reduction was maintained for 3 years. One explanation for the reduction in LOS observed in this study could be the numerous accepted interventions targeting a switch from intravenous to oral therapy (n ¼ 832), or antimicrobial discontinuation and reduction in the duration of antimicrobial administration (n ¼ 1127). These interventions are known to facilitate early hospital discharge. 30 Based on two recent systematic reviews on the subject, 9, 31 this is the only study to demonstrate an important and sustained reduction in average LOS following a PAF initiative.
Most studies evaluating PAF strategies have reported a favourable effect on antimicrobial consumption. We reported a significant decrease in antimicrobial use after the implementation of our PAF strategy. This result is important because our study was performed for all hospitalized adults in two geographically distinct centres with one centralized pharmacist; we did not restrict the intervention to specific units, which otherwise could have been more receptive to feedback or might have had higher rates of antimicrobial use prior to our intervention. Moreover, the study duration was 5 years and included 2 years of pre-intervention data. This approach strengthens the reported results, as the observed trend changes are less likely to be due to short-term non-related variations (e.g. seasonality).
Another important result is the positive impact of the intervention on the concordance of antimicrobial prescriptions with the best practice guidelines included in the knowledge base of APSS. We measured an immediate level change of À2.3% in antimicrobial non-concordance in the ASP period. The observed reduction represents 5005 fewer DOT of non-concordant antimicrobial treatment between the last pre-intervention year and the last ASP year. This result is consistent with the findings of a recent study 32 where the authors reported an overall reduction of 0.6% in non-concordance in antimicrobial prescriptions following the implementation of a computerized clinical decision-support system. Improving antimicrobial prescription might have contributed to the decrease in the average LOS.
Finally, the strong reduction reported in antimicrobial spending was a key factor in convincing the pharmacy and hospital management to maintain the use of APSS to support the ASP. The evaluation of the ASP showed reductions in spending using both variable prices and fixed prices. We used two different outcomes to assess the impact of the APSS-initiated PAF strategy to provide a comprehensive account of the introduction of generic imipenem and meropenem. We cannot separate the impact of the introduction of the generic formulations from the impact of the intervention because recommending cheaper alternatives by, for example, limiting the use of meropenem by replacing it with generic imipenem, was a part of the intervention. The fixed-price model allowed us to exclude the impact of the generic formulations and demonstrated a significant reduction in costs compared with both the conservative mean (À28.3%) and the maximum prediction (À52.5%). The variable-price model also demonstrated a significant reduction compared with the conservative mean (À33.6%) and the maximum prediction (À49.0%). In the segmented regression analysis, the introduction of generic formulations of carbapenems was modelled as a confounding intervention. Only the generic formulation of meropenem had a significant impact and only for the fixed-price outcomes. In the fixed-price model, the Impact of antimicrobial stewardship JAC introduction of generic meropenem showed an important level change of $33 669 per 4 week period. We believe that the ASP team might have placed less emphasis on replacing meropenem prescription because its cost was drastically reduced. After adjustment for the introduction of generic meropenem, our segmented regression analysis showed similar results for the fixed-price model and the variable-price model, with a strong level change and significant negative trend (Table 1) . Locally, the hospital administration noted that the APSS-initiated PAF strategy is associated with annual direct savings of $350 000 (20.5% of the antimicrobial budget), which outweighing the cost of the intervention, which includes the APSS licence, a full-time pharmacist and an hour a day of an infectious diseases physician. An in-depth evaluation of the indirect savings would be of great interest. Due to the inconsistencies in the microbiological data, we were unable to evaluate the impact of this programme on Nault et al.
resistance and nosocomial infection rates. Indirect savings for the reduction of LOS for patients receiving antimicrobials could be estimated. Taking into account the average cost of a stay in a Canadian hospital ($6983) 33 and an average hospital LOS (7.7 days), 34 we estimated that the À2.3 days average LOS observed in this study represents indirect savings of $2085 per hospitalization in which the patient received antimicrobials.
This study had some limitations as it reports results from only one centre, where physicians were receptive to a pharmacist feedback approach. 35 Because the CHUS is a teaching hospital, it has medical residents in most departments, which facilitates response to feedback, since at least one member of the team is available at any time. In addition, we did not measure the impact of the programme on bacterial resistance, because it was impossible to obtain exhaustive data for the entire duration of the study. Even if we had 2 years of data prior to the intervention and 3 years of data thereafter, adjustment for confounders would not be absolute due to the absence of randomization, and the presence of remaining confounders may have influenced our results. Also, the impact of an intervention such as this may rely on the training, experience and skills of the individual pharmacists delivering the intervention and may not be reproducible in other hospitals.
The implementation of an ASP supported by APSS, a novel computerized clinical decision-support system, had a positive impact on antimicrobial use and costs, LOS and non-concordance with guidelines for prescribing antimicrobials. Our intervention was well received by the prescribing physicians. The impacts of the ASP articulated around APSS, a computerized clinical decision-support system that performs a systematic review of all prescribed antimicrobials, were financially and clinically significant for the hospital.
